Squarepoint Ops LLC Boosts Stake in Arcus Biosciences, Inc. $RCUS

Squarepoint Ops LLC lifted its stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS) by 163.7% in the second quarter, according to its most recent filing with the SEC. The fund owned 199,649 shares of the company’s stock after acquiring an additional 123,938 shares during the period. Squarepoint Ops LLC owned approximately 0.19% of Arcus Biosciences worth $1,625,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in Arcus Biosciences by 24.1% during the first quarter. Vanguard Group Inc. now owns 6,687,800 shares of the company’s stock valued at $52,499,000 after purchasing an additional 1,298,584 shares in the last quarter. Woodline Partners LP increased its position in shares of Arcus Biosciences by 45.5% during the 1st quarter. Woodline Partners LP now owns 5,127,304 shares of the company’s stock valued at $40,249,000 after purchasing an additional 1,603,367 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Arcus Biosciences by 14.9% during the 2nd quarter. Geode Capital Management LLC now owns 1,596,329 shares of the company’s stock valued at $12,995,000 after buying an additional 207,097 shares in the last quarter. Sofinnova Investments Inc. raised its holdings in shares of Arcus Biosciences by 17.2% during the 2nd quarter. Sofinnova Investments Inc. now owns 1,216,016 shares of the company’s stock valued at $9,898,000 after buying an additional 178,240 shares in the last quarter. Finally, Millennium Management LLC lifted its position in Arcus Biosciences by 29.2% in the 1st quarter. Millennium Management LLC now owns 1,194,622 shares of the company’s stock worth $9,378,000 after buying an additional 270,253 shares during the last quarter. Institutional investors own 92.89% of the company’s stock.

Arcus Biosciences News Roundup

Here are the key news stories impacting Arcus Biosciences this week:

• Positive Sentiment: Arcus will present at the 44th Annual J.P. Morgan Healthcare Conference on Jan. 14, 2026 — a high‑visibility forum that can accelerate investor interest, provide clinical/program updates and attract buy‑side attention ahead of catalysts. Arcus to Present at JPM
• Neutral Sentiment: Recent analyst notes are mixed-to-constructive: some firms raised price targets and UBS/Bank of America reaffirmed coverage, producing a consensus “Moderate Buy” and an elevated average target — this supports upside but depends on upcoming clinical and commercial news. MarketBeat analyst summary
• Negative Sentiment: Significant, clustered insider selling occurred Dec. 16–18: CEO Terry Rosen sold large blocks (multiple filings totaling ~54k shares across two days), and other senior officers (CFO, COO, President, CAO, General Counsel and others) also sold shares — this concentrated executive selling is likely weighing on sentiment and may prompt short‑term selling pressure. See CEO SEC filing for details. CEO Form 4
• Negative Sentiment: Additional insider sales (CAO Alexander Azoy, CFO Robert Goeltz II, COO Jennifer Jarrett, President Juan Jaen, General Counsel Carolyn Tang, and insider Richard Markus) were filed and aggregated to meaningful dollar amounts — investors often interpret broad leadership selling as a negative signal even when trades may be for diversification or tax reasons. InsiderTrades summary

Analyst Upgrades and Downgrades

A number of brokerages have commented on RCUS. Citigroup reiterated a “buy” rating on shares of Arcus Biosciences in a research report on Friday, December 12th. HC Wainwright increased their target price on shares of Arcus Biosciences from $28.00 to $32.00 and gave the company a “buy” rating in a report on Friday, December 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcus Biosciences in a research note on Wednesday, October 8th. UBS Group reissued a “buy” rating on shares of Arcus Biosciences in a research note on Monday. Finally, Wall Street Zen upgraded Arcus Biosciences from a “sell” rating to a “hold” rating in a research report on Sunday, December 14th. Eight investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $28.89.

Insider Activity

In other news, CEO Terry J. Rosen sold 28,947 shares of the firm’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $21.88, for a total value of $633,360.36. Following the transaction, the chief executive officer directly owned 2,220,553 shares in the company, valued at $48,585,699.64. This trade represents a 1.29% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, COO Jennifer Jarrett sold 37,792 shares of the business’s stock in a transaction dated Wednesday, October 8th. The shares were sold at an average price of $15.05, for a total value of $568,769.60. Following the sale, the chief operating officer owned 214,232 shares of the company’s stock, valued at approximately $3,224,191.60. This represents a 15.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 436,808 shares of company stock valued at $9,239,008 in the last ninety days. 9.60% of the stock is currently owned by company insiders.

Arcus Biosciences Stock Performance

Shares of NYSE RCUS opened at $21.99 on Friday. The firm’s 50-day moving average price is $21.10 and its 200-day moving average price is $14.13. Arcus Biosciences, Inc. has a 52-week low of $6.50 and a 52-week high of $26.40. The company has a market cap of $2.37 billion, a PE ratio of -6.39 and a beta of 0.75. The company has a quick ratio of 3.65, a current ratio of 3.65 and a debt-to-equity ratio of 0.22.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings data on Tuesday, October 28th. The company reported ($1.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.33) by $0.06. Arcus Biosciences had a negative net margin of 136.40% and a negative return on equity of 68.17%. The company had revenue of $26.00 million for the quarter, compared to the consensus estimate of $19.89 million. During the same quarter in the prior year, the firm earned ($1.00) earnings per share. The firm’s revenue for the quarter was down 45.8% compared to the same quarter last year. As a group, analysts anticipate that Arcus Biosciences, Inc. will post -3.15 EPS for the current year.

Arcus Biosciences Profile

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.